Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.

To identify genetic variants associated with outcome from chronic lymphocytic leukemia (CLL), we genotyped 977 nonsynonymous single nucleotide polymorphisms (nsSNPs) in 755 genes with relevance to cancer biology in 425 patients participating in a phase 3 trial comparing the efficacy of fludarabine, chlorambucil, and fludarabine with cyclophosphamide as first-line treatment. Selection of nsSNPs was biased toward those likely to be functionally deleterious. SNP genotypes were linked to individual patient outcome data and response to chemotherapy. The effect of genotype on progression-free survival (PFS) and overall survival (OS) was assessed by Cox regression analysis adjusting for treatment and clinico-pathologic variables. A total of 78 SNPs (51 dominantly acting and a further 27 recessively acting) were associated with PFS (9 also affecting OS) at the 5% level. These included SNPs mapping to the immune-regulation genes IL16 P434S (P = .03), IL19 S213F (P = .001), LILRA4 P27L (P = .004), KLRC4 S29I (P = .007), and CD5 V471A (P = .002); and DNA response genes POLB P242R (P = .04) and TOPBP1 S730L (P = .02), which were all independently prognostic of immunoglobulin heavy-chain variable region (IgV(H)) mutational status. The variants identified warrant further evaluation as promising prognostic markers of patient outcome. To facilitate the identification of prognostic markers through pooled analyses, we have made all data from our analysis publicly available.

[1]  T. Eisen,et al.  Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. , 2007, Human molecular genetics.

[2]  T Hamblin,et al.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.

[3]  D. Weisenburger,et al.  Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia , 2007, Cell.

[4]  Julian Peto,et al.  Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives. , 2006, Human molecular genetics.

[5]  R. Küppers,et al.  The GNAS1 T393C Polymorphism Is Associated with Disease Progression and Survival in Chronic Lymphocytic Leukemia , 2006, Clinical Cancer Research.

[6]  J. Delgado,et al.  Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. , 2006, Leukemia research.

[7]  J. Ajani,et al.  Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Houlston,et al.  Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. , 2006, Blood.

[9]  L. Hiller,et al.  The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia , 2006, Leukemia & lymphoma.

[10]  W. Au,et al.  Tumor necrosis factor alpha promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese population , 2006, Leukemia & lymphoma.

[11]  E. Topol,et al.  Polymorphisms A387P in thrombospondin‐4 and N700S in thrombospondin‐1 perturb calcium binding sites , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  Emily L. Webb,et al.  The Predicted Impact of Coding Single Nucleotide Polymorphisms Database , 2005, Cancer Epidemiology Biomarkers & Prevention.

[13]  D. Clayton,et al.  Population structure, differential bias and genomic control in a large-scale, case-control association study , 2005, Nature Genetics.

[14]  B. Dörken,et al.  In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis , 2005, BMC Cancer.

[15]  C. Fegan,et al.  Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  U. Frey,et al.  Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia , 2004, Leukemia.

[17]  I. M. Jones,et al.  Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. , 2004, Genomics.

[18]  H. Ozçelik,et al.  Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  U. Frey,et al.  1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome , 2004, European journal of haematology.

[20]  S. Amladi,et al.  Online Mendelian Inheritance in Man 'OMIM'. , 2003, Indian journal of dermatology, venereology and leprology.

[21]  Guy Pratt,et al.  The P2X7 receptor gene polymorphism 1513 A→C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl‐2 family protein expression or survival in B‐cell chronic lymphocytic leukaemia , 2003, British journal of haematology.

[22]  M. Lishner,et al.  Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. , 2003, Experimental hematology.

[23]  F. Mancini,et al.  Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. , 2003, Blood.

[24]  M. Lishner,et al.  The antiapoptotic effects of blood constituents in patients with chronic lymphocytic leukemia , 2003, European journal of haematology.

[25]  K. Do,et al.  Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia , 2003, British journal of haematology.

[26]  G. Kolovou,et al.  Apolipoprotein E Polymorphism and Atherosclerosis , 2003, Angiology.

[27]  L. Padyukov,et al.  Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia , 2002, The Lancet.

[28]  D. Sheridan,et al.  Association of a novel single nucleotide polymorphism, G(-248)A, in the 5'-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. , 2002, Cancer letters.

[29]  P. Bork,et al.  Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.

[30]  Martin R. Johnson,et al.  Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  G. Capelli,et al.  Clinical significance of CD38 expression in chronic lymphocytic leukemia. , 2001, Blood.

[32]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[33]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[34]  P. Bork,et al.  Towards a structural basis of human non-synonymous single nucleotide polymorphisms. , 2000, Trends in genetics : TIG.

[35]  D. Valle,et al.  Online Mendelian Inheritance In Man (OMIM) , 2000, Human mutation.

[36]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[37]  Binet Jl.  Prognostic factors in chronic lymphocytic leukaemia. , 1999 .

[38]  H.-S. Kim,et al.  Assignment1 of the human OB binding protein-2 gene (CD33L2) to chromosome 19q13.3 by radiation hybrid mapping , 1999, Cytogenetic and Genome Research.

[39]  G. Juliusson,et al.  Impaired low‐density lipoprotein receptor activity in chronic B‐lymphocytic leukaemia cells , 1988, European journal of haematology.

[40]  R. Grantham.  Amino Acid Difference Formula to Help Explain Protein Evolution , 1974, Science.

[41]  Ncbi.  National Center for Biotechnology Information , 2008 .

[42]  M. Fukushima,et al.  Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase. , 2007, Oncology reports.

[43]  K. Jöckel,et al.  Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. , 2007, Blood.

[44]  H. Döhner,et al.  The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia , 2006, Leukemia.

[45]  Wen-Hsiung Li,et al.  Nonrandomness of point mutation as reflected in nucleotide substitutions in pseudogenes and its evolutionary implications , 2005, Journal of Molecular Evolution.

[46]  T. Stankovic,et al.  Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. , 2004, Blood.

[47]  G. Packham,et al.  Chronic lymphocytic leukemia : revelations from the B-cell receptor , 2004 .

[48]  R. Kurzrock,et al.  Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. , 2001, Blood.

[49]  L. Vilpo,et al.  Interleukin-1 β, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters , 2000 .

[50]  J. Binet.  Prognostic factors in chronic lymphocytic leukaemia. , 1999, Haematologica.